

SETTING THE SCENE:



ADDA BOUNEDJAR



Co-funded by
the European Union




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



VISION EUROPE 2030

DISRUPTIVETECHNOLOGIES, DEMOCRATIZED TRIALS &
NEXT-GEN TREATMENT PARADIGMS



September 2-3, 2025 | Club University Foundation





Precision Frontiers in Chronic Disease

A Global Strategy for Cancer Risk ,Trials and Treatment


Pr Adda BOUNEDJAR
Chairman of medical oncology department
Anti-cancer center Blida university
Algeria



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE





The Global Challenge

Chronic diseases cause 70% of global deaths Cancer: >20 million new cases in

2025, projected 30M by 2040 Major disparities in survival and access Deep

inequalities in access to precision diagnostics and therapies across HDI levels

Ethical and governance dilemmas in data sharing and AI-driven decision-making.

Rising costs of innovation versus sustainability of health systems.


Ensuring equity in global trial participation and not
reinforcing existing gaps.




Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE




- 
- Cancer is now central to global health diplomacy, with WHO's Global Initiative for Childhood Cancer and national cancer control plans driving political momentum.
 - Yet, access remains unequal—high-income countries accelerate genomic and precision medicine, while low- and middle-income countries (LMICs) face major barriers in financing, workforce, and infrastructure.
 - The political will to integrate cancer into Universal Health Coverage (UHC) is growing but uneven.



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Why Vision 2030?


- Innovation in science is accelerating Immunotherapy, CAR-T, mRNA vaccines
- Gene editing & molecular targeting
- AI and digital health to personalize care
- Health systems lag in implementation
- Global collaboration is essential to link discovery → access → equity



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE






Precision in Prevention

- Vaccination & lifestyle interventions
- Early detection and screening
- Genomic risk profiling for targeted prevention



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE






Precision in Clinical Trials

- Biomarker-driven research
- Adaptive & decentralized trials
- Real-world data integration



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE







Equity & Access


- Innovation without access = failure
- Bridging gaps across regions & income levels
- Building genomic and digital equity




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



- 
- Advances in genomics, biomarkers, AI, and real-world data are reshaping risk assessment, early detection, and therapy.
 - Decentralized and adaptive clinical trial models are making innovation more inclusive, but global representation is still limited.
 - Precision medicine is moving beyond oncology into prevention, multi-omics, and chronic disease integration.



- 
- Patients demand equitable access, transparency in data use, and culturally sensitive care.
 - The patient voice is reshaping trial design (patient-reported outcomes, quality of life measures) and expanding definitions of success beyond survival to survivorship and well-being.
 - Stigma, financial toxicity, and geographic disparities remain key patient-level challenges



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Key Opportunities

● Opportunities


- Harnessing AI and big data for global cancer risk stratification and trial efficiency.
- Building regional trial networks that include underrepresented populations.
- Precision prevention: leveraging genomics, lifestyle data, and environment for earlier intervention.
- Cross-sector partnerships (academia, pharma, policymakers, patient advocacy) to accelerate translation into care.



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Discussion


1. Equity & Access: How can global stakeholders ensure that precision medicine does not widen the gap between high- and low-resource settings?
2. Innovation vs. Sustainability: What models of financing and regulation can balance innovation with affordability?
3. Data & AI: What governance frameworks are needed to ensure ethical use of genomic and real-world data while fostering global collaboration?
4. Trials of the Future: How can adaptive, pragmatic, and decentralized trials be designed to reflect global diversity in patient populations?
5. Patients First: In what ways should patient advocacy movements reshape the cancer research and care agenda toward Vision 2030?
6. Integration Beyond Cancer: Can the precision frontiers developed in oncology be a blueprint for other chronic diseases?



Co-funded by
the European Union



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE






Looking Ahead to 2030

- Reduce cancer mortality globally
- Improve survival and quality of life
- Strengthen prevention, research, and access frameworks



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE





Closing Message

- Vision 2030 = Innovation + Equity + Global Solidarity
- A shared commitment to transform cancer care worldwide



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

